Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]
News [3529]
Articles [90]
Editorials [5]
Conferences [156]
elearning [19]
Role of biomarkers, targeted therapy and tumour mutations in the landscape of...
Prof Petros Grivas and Dr Michiel Van der Heijden
Role of biomarkers, targeted therapy and tumour mutations in the landscape of bladder cancer ( Prof Petros Grivas and Dr Michiel Van der Heijden )
30 Sep 2019
Comment: Immunotherapy plus chemotherapy in bladder cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: Immunotherapy plus chemotherapy in bladder cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019
Atezolizumab added to chemotherapy prolongs progression free survival in...
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )
30 Sep 2019
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019
Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )
30 Sep 2019
Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
29 Sep 2019
KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
29 Sep 2019
Comment: Keynote 522 trial
Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy
Comment: Keynote 522 trial ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )
29 Sep 2019
Immunotherapy added to chemotherapy improves pathological complete response in...
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
29 Sep 2019
ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous...
Prof Byoung Chul Cho - Yonsei University, Seoul, South Korea
ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous cell carcinoma ( Prof Byoung Chul Cho - Yonsei University, Seoul, South Korea )
29 Sep 2019
Ovarian highlights from ESMO 2019
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
Ovarian highlights from ESMO 2019 ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )
28 Sep 2019
VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian...
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )
28 Sep 2019
Comment: Nivolumab plus ipilimumab combination for advanced NSCLC
Dr Marina Garassino - National Tumor Institute, Milan, Italy
Comment: Nivolumab plus ipilimumab combination for advanced NSCLC ( Dr Marina Garassino - National Tumor Institute, Milan, Italy )
28 Sep 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation